17.11.2015 • News • biologic • Diabetes • Elaine Burridge

Janssen Boosts Metabolism Portfolio with Hanmi Biologic

US-based drugs firm Janssen Pharmaceuticals has gained worldwide rights, excluding China and Korea, to develop and commercialize oxyntomodulin-based treatments for diabetes and obesity from Hanmi Pharmaceutical. Terms of the deal were not revealed.

The therapies include HM12525A, a biologic which is currently completing Phase 1 trials, and is expected to enter Phase 2 studies next year. It has shown evidence of improving blood glucose, body weight and insulin sensitivity.

Janssen said HM12525A has the potential to be a best-in-class therapy, allowing the company to build on its success in diabetes and strengthen its portfolio of treatments for metabolic diseases.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Top-Feature